Hofseth BioCare ASA (HBC.OL)
NOK 1.95
(0.0%)
NOK 1.95
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 97.1 Million NOK | 6.97% |
| 2022 | 90.77 Million NOK | -27.19% |
| 2021 | 124.66 Million NOK | 39.77% |
| 2020 | 89.19 Million NOK | -13.83% |
| 2019 | 103.51 Million NOK | 240.63% |
| 2018 | 30.38 Million NOK | -31.47% |
| 2017 | 44.34 Million NOK | -2.84% |
| 2016 | 45.63 Million NOK | -46.97% |
| 2015 | 86.06 Million NOK | 91.11% |
| 2014 | 45.03 Million NOK | 25.94% |
| 2013 | 35.76 Million NOK | 17.9% |
| 2012 | 30.33 Million NOK | 35.33% |
| 2011 | 22.41 Million NOK | 664.43% |
| 2010 | 2.93 Million NOK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 95.68 Million NOK | 35209.59% |
| 2024 Q2 | 92.46 Million NOK | -3.37% |
| 2023 Q3 | 87.88 Million NOK | -2.15% |
| 2023 Q4 | 97.1 Million NOK | 10.49% |
| 2023 FY | 97.1 Million NOK | 6.97% |
| 2023 Q1 | 88.9 Million NOK | -2.06% |
| 2023 Q2 | 89.81 Million NOK | 1.02% |
| 2022 Q1 | 120.98 Million NOK | -2.95% |
| 2022 FY | 90.77 Million NOK | -27.19% |
| 2022 Q4 | 90.77 Million NOK | -1.96% |
| 2022 Q3 | 92.58 Million NOK | -36.2% |
| 2022 Q2 | 145.12 Million NOK | 19.95% |
| 2021 Q2 | 117.26 Million NOK | 36.28% |
| 2021 FY | 124.66 Million NOK | 39.77% |
| 2021 Q1 | 86.04 Million NOK | -3.53% |
| 2021 Q3 | 128.9 Million NOK | 9.92% |
| 2021 Q4 | 124.66 Million NOK | -3.29% |
| 2020 Q2 | 94.12 Million NOK | -14.06% |
| 2020 Q1 | 109.51 Million NOK | 5.8% |
| 2020 FY | 89.19 Million NOK | -13.83% |
| 2020 Q3 | 92.66 Million NOK | -1.55% |
| 2020 Q4 | 89.19 Million NOK | -3.74% |
| 2019 Q3 | 110.16 Million NOK | 20.1% |
| 2019 FY | 103.51 Million NOK | 240.63% |
| 2019 Q1 | 95.51 Million NOK | 214.32% |
| 2019 Q4 | 103.51 Million NOK | -6.04% |
| 2019 Q2 | 91.72 Million NOK | -3.97% |
| 2018 Q1 | 42.89 Million NOK | -3.26% |
| 2018 FY | 30.38 Million NOK | -31.47% |
| 2018 Q4 | 30.38 Million NOK | -8.97% |
| 2018 Q2 | 41.67 Million NOK | -2.85% |
| 2018 Q3 | 33.38 Million NOK | -19.9% |
| 2017 Q2 | 23.85 Million NOK | -10.64% |
| 2017 FY | 44.34 Million NOK | -2.84% |
| 2017 Q4 | 44.34 Million NOK | 38.73% |
| 2017 Q1 | 26.69 Million NOK | -41.5% |
| 2017 Q3 | 31.96 Million NOK | 33.98% |
| 2016 Q4 | 45.63 Million NOK | -18.23% |
| 2016 FY | 45.63 Million NOK | -46.97% |
| 2016 Q1 | 85.73 Million NOK | -0.38% |
| 2016 Q2 | 80.71 Million NOK | -5.86% |
| 2016 Q3 | 55.81 Million NOK | -30.85% |
| 2015 Q1 | 33.57 Million NOK | -25.44% |
| 2015 FY | 86.06 Million NOK | 91.11% |
| 2015 Q4 | 86.06 Million NOK | 12.3% |
| 2015 Q3 | 76.64 Million NOK | 1.36% |
| 2015 Q2 | 75.61 Million NOK | 125.18% |
| 2014 Q2 | 41.43 Million NOK | 9.49% |
| 2014 FY | 45.03 Million NOK | 25.94% |
| 2014 Q1 | 37.84 Million NOK | 5.83% |
| 2014 Q4 | 45.03 Million NOK | 31.37% |
| 2014 Q3 | 34.28 Million NOK | -17.27% |
| 2013 Q4 | 35.76 Million NOK | -39.35% |
| 2013 Q2 | 65.37 Million NOK | -6.85% |
| 2013 Q1 | 70.18 Million NOK | 131.39% |
| 2013 FY | 35.76 Million NOK | 17.9% |
| 2013 Q3 | 58.96 Million NOK | -9.8% |
| 2012 Q3 | 33.62 Million NOK | 140.97% |
| 2012 Q1 | 22.31 Million NOK | -0.43% |
| 2012 FY | 30.33 Million NOK | 35.33% |
| 2012 Q2 | 13.95 Million NOK | -37.48% |
| 2012 Q4 | 30.33 Million NOK | -9.79% |
| 2011 Q4 | 22.41 Million NOK | 41.47% |
| 2011 Q3 | 15.84 Million NOK | 0.0% |
| 2011 FY | 22.41 Million NOK | 664.43% |
| 2010 FY | 2.93 Million NOK | 0.0% |
| 2010 Q4 | 2.93 Million NOK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Arctic Bioscience AS | 2.04 Million NOK | -4639.619% |
| Aqua Bio Technology ASA | - NOK | -Infinity% |
| ArcticZymes Technologies ASA | 8.41 Million NOK | -1054.053% |
| BerGenBio ASA | - NOK | -Infinity% |
| PCI Biotech Holding ASA | - NOK | -Infinity% |
| Thor Medical ASA | - NOK | -Infinity% |
| Ultimovacs ASA | 1.88 Million NOK | -5048.568% |